2 citations
,
January 2025 in “Cutis” This review examined the dermatologic side effects and potential treatments benefits of metformin and GLP-1/GIP agonists in managing skin conditions related to hormonal and immune effects in individuals with type 2 diabetes who are overweight or obese.
10 citations
,
August 2012 in “Clinical Pharmacokinectics” This study found that type 2 diabetes mellitus does not affect the pharmacokinetics of metformin in obese pregnant women with PCOS, suggesting no need for dosage adjustments.
July 2026 in “Journal of the American Academy of Dermatology” GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.
1 citations
,
November 2022 in “Journal of the Endocrine Society” This study found that US adults with classic congenital adrenal hyperplasia most preferred a hypothetical adjunctive therapy that prevents glucocorticoid-induced weight gain over other potential benefits.
December 2014 in “Endocrinología y nutrición” The woman's rare combination of diseases suggests an unknown factor may predispose individuals to multiple endocrine diseases.